ArticleThe CRISPR journal2020
Targeted RNA Knockdown by a Type III CRISPR-Cas Complex in Zebrafish.
Article in The CRISPR journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Structural insight into IscB's RNA-lid-based inactivation mechanism.Nature structural & molecular biology · 2026Article
- Enhancing Specificity, Precision, Accessibility, Flexibility, and Safety to Overcome Traditional CRISPR/Cas Editing Challenges and Shape Future Innovations.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Zebrafishology, study design guidelines for rigorous and reproducible data using zebrafish.Communications biology · 2025Review
- Enhanced RNA-targeting CRISPR-Cas technology in zebrafish.Nature communications · 2025Article
- Insight into crRNA Processing inInternational journal of molecular sciences · 2025Article
- A recombinase-activated ribozyme to knock down endogenous gene expression in zebrafish.PLoS genetics · 2025Article
- Enhanced RNA-targeting CRISPR-Cas technology in zebrafish.bioRxiv : the preprint server for biology · 2024Article
- The rise and future of CRISPR-based approaches for high-throughput genomics.FEMS microbiology reviews · 2024Review
- CRISPR technologies for genome, epigenome and transcriptome editing.Nature reviews. Molecular cell biology · 2024Review
- Repair of CRISPR-guided RNA breaks enables site-specific RNA excision in human cells.Science (New York, N.Y.) · 2024Article
- Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases.Nature biotechnology · 2024Article
- CRISPR-based engineering of RNA viruses.Science advances · 2023Article
- Precise transcript targeting by CRISPR-Csm complexes.Nature biotechnology · 2023Article
- CRISPR-based engineering of RNA viruses.bioRxiv : the preprint server for biology · 2023Article
- RNA-Dependent RNA Targeting by CRISPR-Cas Systems: Characterizations and Applications.International journal of molecular sciences · 2023Review
- Targeted DNA integration in human cells without double-strand breaks using CRISPR RNA-guided transposases.bioRxiv : the preprint server for biology · 2023Article
- Type III-A CRISPR systems as a versatile gene knockdown technology.RNA (New York, N.Y.) · 2022Article
- Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses.Nucleic acids research · 2022Article
- Reprogramming CRISPR-Mediated RNA Interference for Silencing of Essential Genes in Sulfolobales.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Recent advances in the use of CRISPR/Cas for understanding the early development of molecular gaps in glial cells.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference is a powerful experimental tool for RNA knockdown, but not all organisms are amenable. Here, we provide a proof of principle demonstration that a type III Csm effector complex can be used for programmable mRNA transcript degradation in eukaryotes. In zebrafish,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.